|
|
Article: Curis Updates Research on Hedgehog Agonist Protein Program for Cardiovascular Disease Indications.
- Article from:
- Business Wire
- Article date:
- August 28, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, today announced that it was notified by one of its corporate partners, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), that preliminary data with a protein agonist of the Sonic Hedgehog (Shh) signaling pathway showed promising results in an established, early preclinical cardiovascular animal model. These positive results are consistent with previously published third-party data in which upregulation of the Shh pathway were demonstrated to be efficacious. Research using Shh protein agonists in various ...
Related newspaper, magazine, and journal articles:
|
|
Article: Curis Reaches First Preclinical Milestone in Hair Growth ...
Business Wire;
March 21, 2006 ;
700+ words
... ... control repair and regeneration. Curis' product development involves ... to modulate these pathways. Curis has successfully used this technology ... Johnson & Johnson), and cardiovascular disease. Curis also possesses robust small molecule ...
|
|